AHF: ‘No More Tears for J and J Greed!’
Drug pricing advocates target Johnson & Johnson, once one of America’s most trusted brands, after New Jersey company contributes $5.8 million to committee to thwart California ballot measure seeking lower drug prices.
AIDS Healthcare Foundation and other advocates for reducing skyrocketing specialty drug prices unveiled a new marketing and public awareness campaign this week in New Brunswick, NJ, the global headquarters of Johnson & Johnson, Inc., admonishing the pharmaceutical giant for contributing $5.8 million dollars to oppose a California ballot initiative that would lower drug prices across the state. Drawing upon the company’s signature branding for its best-selling baby shampoo, a mobile billboard with the message “No More Tears for Greed” will circulate in the vicinity of the Johnson & Johnson campus. In a shocking decision that underscores Johnson & Johnson’s heavyweight influence in the local region and beyond, the move to launch a mobile billboard campaign was made in response to an outdoor advertising company rejecting the drug pricing advocates’ efforts to run paid billboards near the company’s headquarters. The ads will also appear in nearby transit stations.
In addition, street teams have begun distributing palm cards near the Johnson & Johnson campus to inform local residents and workers of the company’s multi-million dollar contributions to derail the California Drug Price Relief Act, a November 2016 California ballot measure that would mandate government health programs pay no more for prescription drugs than the US Department of Veterans Affairs, which typically gets deep discounts on medications from drug manufacturers.
“It’s truly sad and disappointing that one of the most well-known and trusted companies in America is using its vast resources to try to keep drug prices at their outrageously high levels,” said Michael Weinstein, president of AIDS Healthcare Foundation (AHF) and one of the citizen proponents of the California Drug Price Relief Act. “In 2014, Johnson & Johnson reported making over $16 billion in profit, an 18% increase from the previous year. With those kind of returns, it’s absolutely appalling that this corporate giant would lead the way to oppose grassroots efforts to help the little man—everyday citizens who depend on health agencies and insurers having access to the medications they need. For people living with HIV/AIDS, this is a life-or-death situation.”
While soaring drug prices continue to place undue burden on public health agencies and insurers across the country and drugmakers rake in billions in profits, the pharmaceutical industry’s powerful lobbying arm, Pharmaceutical Research and Manufacturers of America (PhRMA), has established a fund of more than $10 million to fight the California Drug Price Relief Act. According to California Secretary of State public fillings, Johnson & Johnson is the largest contributor to the fund, with $5.86 million donated to date. Drugmakers Amgen ($4.265 million), AstraZeneca Pharmaceuticals LP ($4.15 million), AbbVie Inc. ($4.15 million), (Novartis ($2.88 million), Eli Lily ($2.88 million), Bristol-Myers Squibb Co. ($2.88 million), Otsuka America, Inc. ($1.075 million) and Purdue Pharma LP ($1.105 million) are among the companies who have also contributed millions of dollars to oppose the measure and keep drug prices — and profits — at record levels.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance